Global Veterinary Pharmacovigilance Market Size, Trend & Opportunity Analysis Report, by Solution (Software, Services), Type (In-house), and Forecast, 2024–2035

Market Definition and Introduction

The global veterinary pharmacovigilance market was valued at USD 913.9 million in 2024 and is anticipated to reach USD 3,825.25 million by 2035, expanding at a CAGR of 13.9% during the forecast period (2024–2035). Pharmacovigilance, once only externally supporting veterinary health systems, has now taken centre stage in global veterinary affairs with increasing worries about drug safety and regulatory compliance. The need for veterinary medicines is escalated by the unique emotional bond between humans and companion animals and by the increasing demand for livestock products to satiate the world's appetite for protein. This surge is accompanied by, and is therefore likely to magnify, safety responsibilities, as adverse drug reactions in animals are viewed not only from the perspectives of animal welfare but potentially with deleterious outcomes in public health, food safety, and international trade. Thus, the veterinary pharmacovigilance market is propelled forward as regulatory bodies establish incentives for setting up systematic monitoring, data collection and reporting of adverse events for all categories of animals.

Thus, pharmacovigilance solutions provided by software are rapidly being embraced in the digital transformation of veterinary practices and research. Such systems apply artificial intelligence and machine learning in the early identification of adverse drug patterns, thus lowering risks and augmenting compliance with pharmacovigilance frameworks set by institutions like the European Medicines Agency and the U.S. Food and Drug Administration. Meanwhile, services for data management, consultancy, and training are also flourishing as organisations increasingly seek external expertise to navigate complex regulatory landscapes. The combination of digitalisation with stricter oversight and the One Health principle, which links human, animal, and environmental health, has created a very conducive environment for market growth.

Furthermore, increased investment from the pharmaceutical industry in animal drug research, including antiparasitics, vaccines, and antibiotics, also requires sufficiently strong pharmacovigilance practices to ensure product safety and sustain public trust. The general shift to evidence-based veterinary medicine also underscores the demand for comprehensive pharmacovigilance systems that can locally identify safety signals and minimise risks for market recalls and damage to manufacturer reputations. This change is not merely technical, but is also cultural, with stakeholders across the veterinary value chain starting to see pharmacovigilance as a strategic enabler instead of just an operational burden.

Recent Developments in the Industry

Oracle Corporation has lifted the veil on a greatly advanced AI-enabled pharmacovigilance solution for monitoring veterinary drugs.

In March 2024, Oracle Corporation unveiled a cloud-based pharmacovigilance system with specially designed signal detection capabilities powered by AI for veterinary drugs. This end-to-end monitoring platform integrates adverse event reporting with predictive analytics to enable veterinary pharmaceutical companies to improve drug safety and regulatory compliance. The development is an example of the broader industry shift toward digitisation and advanced automation.

Zoetis furthers regulatory compliance by forming a strategic alliance with Veeva Systems Inc.

In August 2024, the partnership between Zoetis and Veeva Systems sought to integrate cloud-based pharmacovigilance management tools into Zoetis' global operations. This integration allows for the smooth collection and submission of adverse drug events in compliance with international standards. By using Veeva's regulatory platform, Zoetis seeks to improve response times while minimising compliance risks across different markets.

Indegene invests in the next-gen pharmacovigilance outsourcing services for veterinary pharmaceuticals.

In November 2023, Indegene increased its service portfolio to include veterinary pharmacovigilance outsourcing that offers customised monitoring and case management and regulatory submission services. The investment comes in keeping with the growing trends of pharmaceutical companies attempting to transfer non-core functions to specialised service providers. It strengthens Indegene's standing as a worldwide partner in the area of veterinary drug safety management.

Market Dynamics

Pharmacovigilance Solution Needs Increasing Speedy Demand to Manage Safety of Veterinary Drugs Is One of the Driving Factors for the Growth of the Global Market.

The rise in the development and utilisation of veterinary medicines for livestock and companion animals has made pharmacovigilance an essential tool for animal welfare. Pharmaceutical companies and veterinarians highly adopt pharmacovigilance solutions to ensure the safety of animals and prevent adverse drug reactions, and ensure that they comply with the upcoming stringent regulations on pharmacovigilance. Increasing awareness of zoonotic hazards, government investments in animal health care, and the inroads made by predictive AI-enabled software platforms for drug safety profiles favourably impact quite a lot of states.

High implementation costs and data complexity hinder the rapid adoption of veterinary pharmacovigilance systems.

However, the high cost of entry, combined with the complexities involved in dealing with considerable volumes of diversity in veterinary data, is proving to be an important restraining force. Most veterinary establishments in developing countries cannot raise sufficient funds to put infrastructure in place for implementing advanced pharmacovigilance systems. Furthermore, practice management systems integration challenges add to the inefficiency in the operations of the smaller players in the field.

Apart from regulatory constraints and lack of expertise, pharmacovigilance compliance is stymied by other unique barriers.

Veterinary pharmacovigilance systems remain unfinished or evolving, as regulatory harmonisation is still pending on different continents. A diverse framework of regulations exists in such a fragmented regulatory environment, through which a multinational company must be compliant. The situation is further aggravated by the inadequacy of pharmacovigilance-trained professionals with veterinary knowledge, which limits the models of service scalability. Such challenges force entities into making huge investments in training and outsourcing; thus, operational costs are heightened.

Revolutionising Veterinary Pharmacovigilance through Digital Transformation and Artificial Intelligence Integration.

Artificial intelligence, natural language processing, and cloud computing revolutionise the pharmacovigilance platform and create new opportunities in proactive risk assessment. These technologies also streamline regulatory requirements by automating adversity event detection and thereby minimising manual workloads and human error. Strategic outsourcing is embraced, with service providers tailoring solutions to companies available in outsourced services for compliance management. Long-term significant growth opportunities are envisaged to be opened by this wave of technology.

Increased worldwide focus towards One Health and zoonotic disease surveillance enhances the adoption of Pharmacovigilance.

The COVID-19 pandemic has brought a sharper focus on zoonoses, prompting global health agencies to take up animal drug safety issues within the One Health dimension. This has consequently directed investments in veterinary pharmacovigilance infrastructure as a global preventative measure against public health risks by the government and international entities. As a result, pharmacovigilance will increasingly be seen not just as a veterinary asset but also as a public health insurance, as it becomes recognised by more countries.

Attractive Opportunities in the Market

AI-Powered Platforms Expansion – Rapid integration of artificial intelligence enhances predictive safety monitoring across veterinary drugs globally.
Outsourced PV Services Rise – Pharmaceutical firms outsource pharmacovigilance to specialised providers, reducing compliance costs and boosting efficiency.
One Health Integration – Global health bodies prioritise animal drug safety within zoonotic disease prevention and surveillance strategies.
Regulatory Harmonisation Efforts – Emerging collaboration among agencies fosters uniform standards for veterinary pharmacovigilance reporting and compliance.
Cloud Adoption Surge – Cloud-based pharmacovigilance solutions streamline data collection, reporting, and global regulatory submissions.
Pharma R&D Investments – Growing veterinary drug pipeline boosts demand for robust pharmacovigilance systems to mitigate risks.
Digital Record Systems – Integration of pharmacovigilance into practice management systems enables seamless safety data tracking.
Data Analytics Growth – Advanced analytics tools empower early signal detection and actionable insights from complex safety datasets.
Asia-Pacific Demand Growth – Expanding livestock and companion animal healthcare investments accelerate regional pharmacovigilance adoption.
Training & Education Push – Upskilling initiatives enhance the availability of pharmacovigilance professionals with veterinary expertise.

Report Segmentation

By Solution: Software, Services

By Type: In-house

By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)

Key Market Players

ArisGlobal, Oracle Corporation, Ennov, Indegene, Sarjen Systems Pvt. Ltd., Sparta Systems, Zoetis Inc., Veeva Systems Inc., Causality Link, and Vetspire.

Report Aspects

Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 293

Dominating Segments

Software solutions have been the real drivers in the veterinary pharmacovigilance market, with the integration of these new approaches in AI systems and regulatory compliance around them.

Typically, software platforms now dominate the veterinary pharmacovigilance ecosystem because, first and foremost, these systems enable the shift of transformation in practice to the digital environment that tends to prevail on the animal healthcare front. These systems now use automation and artificial intelligence coupled with predictive analysis to demonstrate faster and more accurate detection of adverse drug effects as compared with the normal manual methods. This has increased the need for such platforms, as veterinary pharmaceutical companies, regulators, and even veterinary practices want efficient and more standardised systems that not only monitor all adverse events but also report more easily to such global authorities as the FDA and EMA. The increasing pressure for compliance with the pharmacovigilance requirements has further hastened the proliferation, thus having software solutions as the main growth carrier of the market. Furthermore, the scalability of cloud-based platforms allows broadened access, enabling both large corporations and smaller veterinary practices to manage safety reporting in a streamlined manner. Given the rising commitment toward drug development and a swelling pipeline in the veterinary pharmaceutical sector, it is expected that software systems will hold the lead throughout the forecast period.

The services segment develops as outsourcing models deliver cost-efficient compliance with expertise.

There is a huge space in the services segment within the veterinary pharmacovigilance, especially with the increasing outsourcing of complex functions by pharmaceutical companies to relieve operational burden. Outsourced pharmacovigilance services enable companies to mainly concentrate on drug development and assign compliance management functions to dedicated service providers. The required services include adverse event reporting, case processing, regulatory submission management, and signal detection, which are characterised by highly sophisticated knowledge and technological infrastructure. Outsourcing makes a good case to many emerging players and mid-sized companies, as maintenance of in-house pharmacovigilance teams involves very high costs and a shortage of skills. Hence come service providers customise their solutions to regional regulatory parameters, thus increasing their value proposition. A lively growth trajectory is being forged out in the segment of services, creating strong synergies with software provision in the larger pharmacovigilance ecosystem.

In-house type remains prominent as large veterinary pharmaceutical firms invest in proprietary pharmacovigilance capabilities.

The in-house segment continues to be a major type, as most of the global veterinary pharmaceutical giants have been investing heavily in developing strong internal pharmacovigilance departments. Most of these companies have the financial base, technical backbone, and regulatory know-how to sustain a well-managed pharmacovigilance unit. In-house operations often allow greater company control over safety monitoring processes, faster availability of proprietary safety data and improved confidentiality in dealing with adverse events. Besides, in-house nature often allows pharmacovigilance to be seamlessly incorporated into R&D pipelines and clinical trials, allowing for much faster treatment of safety signals. Commercialisation models have gained quite a reputation in recent times, but having in-house pharmacovigilance systems is absolutely a must for those large-scale manufacturers that have a global market reach, because world-level vigilance and compliance inspection needs to be very strict all through. Indeed, this is not just a function of capacity in the organisation, but the strategic importance of pharmacovigilance as the next most valuable differentiator in market credibility and regulatory trust.

Key Takeaways

Software Platforms Lead – AI-driven pharmacovigilance software dominates, streamlining adverse event monitoring and regulatory reporting globally.
Service Outsourcing Grows – Outsourced pharmacovigilance services expand as cost-effective solutions for compliance in smaller organisations.
In-house Strength Prevails – Large veterinary pharmaceutical firms maintain dominance with dedicated internal pharmacovigilance departments.
Digital Transformation Push – Cloud-based and AI-enabled platforms reshape veterinary drug safety monitoring practices worldwide.
One Health Priority – Pharmacovigilance strengthens as a vital link between animal safety and public health.
Regulatory Stringency Rises – Global authorities intensify compliance mandates, driving adoption of pharmacovigilance systems.
Asia-Pacific Momentum – Expanding livestock and companion animal healthcare fuels rapid regional growth.
Workforce Gap Challenge – Shortages of trained professionals hinder the scalability of pharmacovigilance services.
Zoonotic Risk Awareness – Surveillance expansion enhances pharmacovigilance adoption as a preventive global health measure.
Customised PV Models – Service providers tailor pharmacovigilance solutions to regional compliance needs and customer demands.

Regional Insights

North America is the most advanced continent in the veterinary pharmacovigilance market, with some of the strongest pharmaceutical infrastructure and most stringent regulatory supervision.

The North American market, where the major component is presently being led by the USA, is ideally situated due to an established veterinary pharmaceutical industry and stringent drug safety regulations enforced by the FDA. Indeed, the region features state-of-the-art infrastructure along with increasingly cloud-based pharmacovigilance solutions with an even earlier adopter culture of innovative technology applications. Investment in-house by pharmaceutical companies located throughout the U.S. and Canada really runs deep to form partnerships with special service providers. Coupled with the rising awareness of zoonotic diseases toward the increasing companion animals, pharmacovigilance is becoming a crucial aspect of the practice. Thus, it is capping off the fast-developing trends toward regulation and technology innovation with enormous integration of artificial intelligence-based monitoring solutions in placing this region as a leader in the global market.

Europe advances in veterinary pharmacovigilance, paving the way for regulatory harmonisation and green pharmacological practices.

Europe keeps being a critical hub for veterinary pharmacovigilance, with strong regulatory frameworks established by the EMA as well as other national agencies. Given the regional tendency towards harmonised pharmacovigilance systems, nations benefit from a greater degree of consistency across member states. Germany, France, and the UK are all spearheading the charge into pharmacovigilance digitalisation, while collaborative efforts are being put in place among most research institutions with pharmaceutical partners to sharpen the monitoring of safety practices across Europe. In addition to being more inclined to sustainable and responsible pharmaceutical practices, Europe has created parallel avenues of opportunity by aligning such laws with its overall green agenda towards transforming and innovating safe veterinary drugs. The One Health approach, coupled with animal welfare standards-enhancing spotlight, gives more weight to the adoption of sophisticated pharmacovigilance systems, making Europe a strong actor in dictating global standards.

Asia-Pacific is emerging as the fastest-growing market, propelled by livestock expansion and digital healthcare penetration.

The fastest growth in veterinary pharmacovigilance was expected in the Asia-Pacific region, as booming livestock industries develop in China, India, and Southeast Asia. Increasingly, countries are becoming urban, with increasing levels of disposable income and pet ownership, which account for increased consumption of veterinary drugs. Growing stricter rules on pharmacovigilance are being put in place in various governments, such as Japan, South Korea, and Australia, and enforced. Local pharmaceutical companies are turning to software platforms and outsourcing services to comply with the regulations, hence driving the region's acceptance. Furthermore, international collaborations and investments in digital health infrastructure are accelerating the integration of AI-driven pharmacovigilance systems. Asia-Pacific, therefore, stands as the most promising growth frontier for the industry with vast animal populations and an expanding healthcare ecosystem.

Pharmacovigilance adopts a slow but steady path amid the gradual growth in animal healthcare infrastructure across LAMEA.

Latin America, the Middle East, and Africa have gradually accepted veterinary pharmacovigilance, but adoption rates vary from one sub-region to another. Notable countries in the adoption of pharmacovigilance at the Latin American level are Brazil and Argentina, since they possess strong livestock industries complemented with an increasing export market for their products that needs to meet international veterinary drug safety standards. Investments in modern veterinary healthcare infrastructure, such as digital pharmacovigilance systems, are reported in countries like the UAE and Saudi Arabia to comply with the global benchmark in the Middle East. Africa is at a very low adoption stage regarding infrastructure, but is beginning to draw more attention to the health and safety of animals because of investment efforts through livestock development programs by governments and NGOs. Although LAMEA is lagging compared with other developed world regions, its gradual progress is indicative of emerging opportunities for solution providers in the space of pharmacovigilance.

Core Strategic Questions Answered in This Report

Q. What is the expected growth trajectory of the veterinary pharmacovigilance market from 2024 to 2035?

The global veterinary pharmacovigilance market is projected to grow from USD 913.9 million in 2024 to USD 3,825.25 million by 2035, registering a CAGR of 13.9%. This rapid growth is driven by increasing demand for veterinary pharmaceuticals, regulatory pressure, and digital innovations in safety monitoring.

Q. Which key factors are fuelling the growth of the veterinary pharmacovigilance market?

Several key factors are propelling market growth:

Rising prevalence of companion animals and expanding livestock healthcare demands
Increased regulatory scrutiny and stricter pharmacovigilance frameworks worldwide
Adoption of AI-powered and cloud-based pharmacovigilance software platforms
Outsourcing trend among veterinary pharmaceutical companies to optimise compliance
Integration of One Health principles connecting animal safety with public health outcomes

Q. What are the primary challenges hindering the growth of the veterinary pharmacovigilance market?

Major challenges include:

High implementation and operational costs for pharmacovigilance systems
Shortage of skilled professionals with veterinary pharmacovigilance expertise
Regulatory fragmentation and lack of harmonised standards across regions
Complexity in handling heterogeneous safety data from diverse animal populations
Limited infrastructure in emerging markets is delaying the adoption of digital systems

Q. Which regions currently lead the veterinary pharmacovigilance market in terms of market share?

North America currently leads the veterinary pharmacovigilance market due to its strong pharmaceutical industry, strict FDA oversight, and advanced digital infrastructure. Europe closely follows, driven by harmonised EMA regulations and strong adoption of pharmacovigilance practices.

Q. What emerging opportunities are anticipated in the veterinary pharmacovigilance market?

The market is ripe with new opportunities, including:

Expansion of AI-driven pharmacovigilance solutions across global markets
Growth of outsourcing services for cost-effective compliance support
Rising adoption of One Health initiatives globally
Development of harmonised regulatory frameworks across regions
Investment in digital healthcare infrastructure and cloud-based platforms

Key Benefits for Stakeholders

The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
Porter’s Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
A detailed examination of market segmentation helps identify existing and emerging opportunities.
Key countries within each region are analysed based on their revenue contributions to the overall market.
The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion. Show more